Screening for ATTR heart amyloid in older HFpEF patients
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how often a specific heart condition (ATTR amyloid) occurs in people age 65+ who have HFpEF. It also tries to predict who might have it, using a special heart scan, and may help your care team identify it earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of HFpEF (heart failure with preserved pumping strength)
- You are 65 years old or older
- Your kidneys are not in the very advanced stage that requires dialysis (eGFR under 15)
- You have not had a negative 99mTc-pyrophosphate heart scan within the last year
- You can lie flat and stay still for 15 minutes during the scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from adults who have been diagnosed with, or are being checked for, ATTR amyloidosis (a condition where abnormal protein builds up in the body) using a heart PYP scan. Your participation may help doctors better understand how these scans relate to diagnosis and follow-up over time.
This study looks back at bone scans that were done for other reasons to see if they can spot a condition called cardiac amyloidosis, where abnormal protein builds up in the heart.
This study tests whether taking a small tissue sample from the right side of the heart during a routine pacemaker or defibrillator procedure can help find a condition called cardiac amyloidosis, which causes stiffening of the heart muscle. It aims to improve early detection in people who already need a cardiac device and may have early signs of the disease.
This study tests a new PET imaging tracer called [18F]FT8 to see if it can better detect amyloid protein buildup in the heart. It may help doctors diagnose and monitor cardiac amyloidosis more accurately.
This study uses a new imaging technique (PET scan with a tracer called evuzamitide) to detect a type of heart disease called cardiac amyloidosis in patients whose standard heart scans were unclear but who have elevated levels of a new blood marker (TAD1). The goal is to find a better way to diagnose this condition.
This study uses a special ultrasound to measure heart stiffness in people 60 and older who have heart failure with preserved or mildly reduced pumping function, with or without a condition called ATTR amyloidosis (a protein buildup in the heart). It also includes healthy controls.
Hear when a new Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.